Disclosures for "Futility in Survival: Predictors of 90-Day Poor Outcomes (mRS 4-5) After Endovascular Thrombectomy for Ischemic Stroke "
-
Mr. Doheim has nothing to disclose.
-
Abdullah Al Qudah has nothing to disclose.
-
Dr. Rios Rocha has nothing to disclose.
-
Miss Almast has nothing to disclose.
-
Dr. Bhatt has nothing to disclose.
-
The institution of Dr. Rocha has received research support from NIH.
-
Dr. Starr has nothing to disclose.
-
Dr. Correia Lima has nothing to disclose.
-
Dr. Lang has nothing to disclose.
-
Dr. Gross has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Gross has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Microvention. Dr. Gross has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AHA.
-
Dr. Nogueira has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, and Synchron (consulting fees) as well as for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse and Perfuze ( stock options). Dr. Nogueira has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law Firms. Dr. Nogueira has received stock or an ownership interest from Viz-AI, Perfuze, Cerebrotech, Reist/Q'Apel Medical, Truvic, and Viseon. The institution of Dr. Nogueira has received research support from Cerenovus.
-
Dr. Al-Bayati has nothing to disclose.